MedPath

Effect of Inhaled Molecular Hydrogen on Recovery Process After Downhill Walking on the Treadmill

Not Applicable
Completed
Conditions
Muscle Fatigue
Oxidative Stress
Muscle Soreness
Inflammation
Interventions
Other: Placebo
Other: Molecular hydrogen
Registration Number
NCT05982665
Lead Sponsor
Palacky University
Brief Summary

This study assesses the effect of molecular hydrogen inhalation in healthy males on muscle soreness, fatigue, oxidative stress, and inflammation following eccentric muscle contraction during downhill walking on the treadmill.

Detailed Description

The main aim of this randomized, double-blind, placebo-controlled crossover study is to assess the effect of molecular hydrogen inhalation on recovery after downhill walking with an additional load of 15% of body mass on the treadmill with a negative slope of -15% at a speed of 6.5 km/h for 90 min. The study includes 12 participants, healthy males aged 20-35 years. The study consists of two experimental sessions, one using molecular hydrogen inhalation and the other using placebo inhalation. Randomization is performed using a computer random generator. Molecular hydrogen is colourless, odourless, and tasteless, so it cannot be distinguished from placebo by the human senses. The washout period between sessions is set at four weeks. One week before each session, participants are asked to follow diet and physical activity rules. Variables measured during the 48 h recovery are as follow: creatine kinase level, perceived muscle soreness, reactive strength index, malondialdehydes level, and interleukin-6 level. The following variables are also measured during exercise: heart rate, ventilation and gas exchange, and blood lactate level. Analysis of variance for repeated measures and Fisher's post hoc tests are used for statistical analysis. The significance level is set at 0.05.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
14
Inclusion Criteria
  • Free of major diseases.
  • Completed questionnaire Sudden Cardiovascular Death in Sport: Lausanne Recommendations.
  • Signed informed consent.
Exclusion Criteria
  • Acute conditions contraindicating laboratory testing of sports performance.
  • Hypertension.
  • Dyslipoproteinaemia.
  • Cardiorespiratory disease.
  • Pharmacotherapy affecting heart rate.
  • Musculoskeletal problems.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo inhalation for 60 min at 48 h, 24 h, and 60 min pre-exercise and for 30 min post-exercise and 24 h post exercise.
Molecular hydrogenMolecular hydrogenMolecular hydrogen inhalation for 60 min at 48 h, 24 h, and 60 min pre-exercise and for 30 min post-exercise and 24 h post exercise.
Primary Outcome Measures
NameTimeMethod
Creatine kinaseChange between values before and after 4 weeks of crossover.

The level of creatine kinase is measured from a venous blood sample taken by a healthcare specialist. Samples are collected in 2.7 ml citrate vacuum tubes. Samples are immediately centrifuged at 1000 g for 15 min and then divided into 0.5 ml cryotubes and frozen at -80 °C. Samples are taken pre-exercise (baseline), post-exercise, and 2 h, 24 h and 48 h post-exercise. Creatine kinase is determined by ELISA method according to the manufacturer's instructions.

Perceived muscle sorenessChange between values before and after 4 weeks of crossover.

A visual analogue scale is used to subjectively assess lower limb muscle soreness. The visual analogue scale is represented by a 100 mm line marked 0 - no pain and 100 - worst imaginable pain. The subject is instructed to mark a point on the line corresponding to their perceived muscle soreness. Muscle soreness is assessed pre-exercise (baseline), post-exercise, and 2 h, 24 h and 48 h post-exercise.

Secondary Outcome Measures
NameTimeMethod
MalondialdehydesChange between values before and after 4 weeks of crossover.

The level of malondialdehydes is measured from a venous blood sample taken by a healthcare specialist. Samples are collected in 2.7 ml citrate vacuum tubes. Samples are immediately centrifuged at 1000 g for 15 min and then divided into 0.5 ml cryotubes and frozen at -80 °C. Samples are taken pre-exercise (baseline), post-exercise, and 2 h post-exercise. Malondialdehydes are determined using TBARS assay kit according to the manufacturer's instructions.

Reactive strength indexChange between values before and after 4 weeks of crossover.

Reactive strength index is determined in 5 maximum hop test on AMTI OR6-7-1000 force platform (Advanced Mechanical Technology, Watertown, USA). Each subject is instructed to maximize the jump height and minimize the ground contact time. Reactive strength index is measured pre-exercise (baseline), post-exercise, and 2 h, 24 h and 48 h post-exercise.

Interleukin-6Change between values before and after 4 weeks of crossover.

The level of Interleukin-6 is measured from a venous blood sample taken by a healthcare specialist. Samples are collected in 2.7 ml citrate vacuum tubes. Samples are immediately centrifuged at 1000 g for 15 min and then divided into 0.5 ml cryotubes and frozen at -80 °C. Samples are taken pre-exercise (baseline), post-exercise, and 2 h post-exercise. Interleukin-6 is determined by ELISA method according to the manufacturer's instructions.

Trial Locations

Locations (1)

Palacky University, Faculty of Physical Culture

🇨🇿

Olomouc, Czechia

© Copyright 2025. All Rights Reserved by MedPath